Sanjeev Arora

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. pmc Expanding access to hepatitis C virus treatment--Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care
    Sanjeev Arora
    University of New Mexico Health Sciences Center, Project ECHO, Albuquerque, NM, USA
    Hepatology 52:1124-33. 2010
  2. pmc Outcomes of treatment for hepatitis C virus infection by primary care providers
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico, Albuquerque, USA
    N Engl J Med 364:2199-207. 2011
  3. pmc Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico
    Sanjeev Arora
    University of New Mexico School of Medicine, Albuquerque, NM 87131 0001, USA
    Public Health Rep 122:74-7. 2007
  4. ncbi request reprint Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    J Gastroenterol Hepatol 21:406-12. 2006
  5. pmc Academic health center management of chronic diseases through knowledge networks: Project ECHO
    Sanjeev Arora
    Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    Acad Med 82:154-60. 2007
  6. doi request reprint Demonopolizing medical knowledge
    Sanjeev Arora
    Dr Arora is professor of medicine and director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Thornton is professor of medicine and associate director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Komaromy is associate professor of medicine and associate director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Kalishman is associate professor and clinician evaluation director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Katzman is associate professor and medical director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Duhigg is assistant professor and psychiatry faculty, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico
    Acad Med 89:30-2. 2014
  7. doi request reprint Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites
    Stanley Yu
    Department of Gastroenterology, University of New Mexico, Albuquerque, New Mexico 87131 0001, USA
    Am J Gastroenterol 104:1686-92. 2009
  8. ncbi request reprint Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study
    Robert G Gish
    Department of Medicine, Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, San Francisco, CA, USA
    J Hepatol 47:51-9. 2007
  9. doi request reprint Building capacity to reduce disparities in diabetes: training community health workers using an integrated distance learning model
    Kathleen Colleran
    Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 0001, USA
    Diabetes Educ 38:386-96. 2012
  10. doi request reprint Taribavirin in the treatment of hepatitis C
    Paulina Deming
    University of New Mexico Health Sciences Center, College of Pharmacy, MSC 09 5360, 1 University of New Mexico, Albuquerque, NM 87131 0001, USA
    Expert Opin Investig Drugs 20:1435-43. 2011

Collaborators

Detail Information

Publications17

  1. pmc Expanding access to hepatitis C virus treatment--Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care
    Sanjeev Arora
    University of New Mexico Health Sciences Center, Project ECHO, Albuquerque, NM, USA
    Hepatology 52:1124-33. 2010
    ....
  2. pmc Outcomes of treatment for hepatitis C virus infection by primary care providers
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico, Albuquerque, USA
    N Engl J Med 364:2199-207. 2011
    ..With the use of video-conferencing technology, the ECHO program trains primary care providers to treat complex diseases...
  3. pmc Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico
    Sanjeev Arora
    University of New Mexico School of Medicine, Albuquerque, NM 87131 0001, USA
    Public Health Rep 122:74-7. 2007
    ..Project ECHO has increased access to state-of-the art hepatitis C virus care for patients living in rural areas or prisons. Because of its success with hepatitis C, this project is being expanded to other chronic medical conditions...
  4. ncbi request reprint Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    J Gastroenterol Hepatol 21:406-12. 2006
    ..HRQoL in the present population was also compared with HRQoL in patients with elevated ALT levels, observed in a previous study...
  5. pmc Academic health center management of chronic diseases through knowledge networks: Project ECHO
    Sanjeev Arora
    Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    Acad Med 82:154-60. 2007
    ....
  6. doi request reprint Demonopolizing medical knowledge
    Sanjeev Arora
    Dr Arora is professor of medicine and director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Thornton is professor of medicine and associate director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Komaromy is associate professor of medicine and associate director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Kalishman is associate professor and clinician evaluation director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Katzman is associate professor and medical director, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Dr Duhigg is assistant professor and psychiatry faculty, Project ECHO Extension for Community Healthcare Outcomes, University of New Mexico Health Sciences Center, Albuquerque, New Mexico
    Acad Med 89:30-2. 2014
    ..The ECHO model increases access to care in rural and underserved areas, and it demonopolizes specialized medical knowledge and expertise. ..
  7. doi request reprint Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites
    Stanley Yu
    Department of Gastroenterology, University of New Mexico, Albuquerque, New Mexico 87131 0001, USA
    Am J Gastroenterol 104:1686-92. 2009
    ..The aim of this study was to compare the treatment responses of Hispanics and non-Hispanic whites (NHW) treated with pegylated interferon and ribavirin for chronic HCV...
  8. ncbi request reprint Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study
    Robert G Gish
    Department of Medicine, Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, San Francisco, CA, USA
    J Hepatol 47:51-9. 2007
    ..Taribavirin, a ribavirin prodrug, has shown a lower incidence of anemia. We sought to determine the efficacy and safety of taribavirin vs. ribavirin combined with pegylated interferon in patients with chronic hepatitis C (CHC)...
  9. doi request reprint Building capacity to reduce disparities in diabetes: training community health workers using an integrated distance learning model
    Kathleen Colleran
    Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 0001, USA
    Diabetes Educ 38:386-96. 2012
    ..The University of New Mexico Health Sciences Center has developed a rigorous diabetes training program for CHWs involving both distance and hands-on learning as part of Project ECHO™ (Extension for Community Healthcare Outcomes)...
  10. doi request reprint Taribavirin in the treatment of hepatitis C
    Paulina Deming
    University of New Mexico Health Sciences Center, College of Pharmacy, MSC 09 5360, 1 University of New Mexico, Albuquerque, NM 87131 0001, USA
    Expert Opin Investig Drugs 20:1435-43. 2011
    ..Taribavirin, a ribavirin prodrug, was designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the subsequent development of hemolytic anemia...
  11. pmc Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care
    Sanjeev Arora
    Project ECHO, University of New Mexico School of Medicine, Albuquerque, Sanjeev Arora, USA
    Health Aff (Millwood) 30:1176-84. 2011
    ..As of March 2011, 298 Project ECHO teams across New Mexico have collaborated on more than 10,000 specialty care consultations for hepatitis C and other chronic diseases...
  12. ncbi request reprint The shocking cost of turnover in health care
    J Deane Waldman
    Health Sciences Center, Anderson Schools of Management, University of New Mexico, Albuquerque, NM, USA
    Health Care Manage Rev 29:2-7. 2004
    ..Here, turnover includes hiring, training, and productivity loss costs. Minimum cost of turnover represented a loss of >5 percent of the total annual operating budget...
  13. doi request reprint Randomized evaluation of a web based interview process for urology resident selection
    Satyan K Shah
    Division of Urology, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131, USA
    J Urol 187:1380-4. 2012
    ..We determined whether a web based interview process for resident selection could effectively replace the traditional on-site interview...
  14. ncbi request reprint Ethical issues in the treatment of hepatitis C
    Cynthia M A Geppert
    New Mexico Veterans Affairs Healthcare System, and Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    Clin Gastroenterol Hepatol 3:937-44. 2005
    ..These barriers to care have received little attention in the literature, and yet, knowledge of the ethical and social justice aspects of HCV treatment can enhance the quality of gastroenterologists' patient care...
  15. doi request reprint Chronic hepatitis C in pregnancy
    Eliza M F Berkley
    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
    Obstet Gynecol 112:304-10. 2008
    ..To estimate outcomes, to determine whether appropriate follow-up was performed for pregnant patients with hepatitis C virus (HCV), and to show that maternal and neonatal complications would be higher in the HCV-positive group...
  16. ncbi request reprint Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy
    Mark Sulkowski
    Viral Hepatitis Center, Johns Hopkins Medical Institutions, 1830 E Monument St, Room 448, Baltimore, MD 21205, USA
    Clin Pharmacol Ther 77:214-24. 2005
    ..Our objective was to quantify the pharmacokinetics of methadone and the pharmacokinetics and pharmacodynamics of peginterferon alfa-2a (40 kd) in patients with chronic hepatitis C undergoing methadone maintenance therapy...
  17. ncbi request reprint Widening the door: the evolution of hepatitis C treatment in patients with psychiatric disorders
    Cynthia M A Geppert
    Hepatology 46:957-9. 2007

Research Grants2

  1. Project ECHO Extension for Community Healthcare Outcomes
    Sanjeev Arora; Fiscal Year: 2006
    ....
  2. Expansion of Rural Health Care Research Infrastructure through the ECHO Model
    Sanjeev Arora; Fiscal Year: 2007
    ..Research Arm on Diabetes, PI Kathleen Colleran, MD Research Arm on Pediatric Overweight, PI Keri Bolton Oetzel, PhD, MPH, LPC Research Arm on Buprenorphine, PI Miriam Komaromy, MD Research Arm on Medical Ethics, PI Anne Simpson, MD, CMD ..